deltatrials
Completed PHASE1 NCT00037817

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Advanced Esophageal Cancers Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura Non-Small-Cell Lung Carcinoma Pleural Mesotheliomas Primary Small Cell Lung Cancers
Interventions Celecoxib Decitabine Depsipeptide
Updated 8 times since 2017 Last updated: Sep 27, 2019 Started: May 17, 2002 Primary completion: Oct 8, 2008 Completion: Nov 9, 2009

Listed as NCT00037817, this PHASE1 trial focuses on Advanced Esophageal Cancers and Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE1

  5. Aug 2018 — Oct 2019 [monthly]

    Completed PHASE1

▶ Show 3 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE1

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States